Prostate Cancer Targeted Therapy: Highlighting Advances in Precision Medicine and Rational Combination Approaches

Dear Colleagues,

The clinical landscape for advanced prostate cancer is rapidly changing. The field is quickly moving toward a targeted paradigm, where individualized patient tumor characteristics will guide treatment decisions, leading to tailored, improved outcomes. Current progress toward the promise of precision medicine for prostate cancer includes PARP inhibitor use for the treatment of tumors with DNA repair defects, pembrolizumab (PD-1 inhibitor) for MMR defective tumors, and the recent approval of ¹⁷⁷Lu-PSMA-617 (Pluvicto) for PSMA-positive mCRPC. Rational combinations of new and available therapies are also improving patient management. Notably, our evolving understanding of AR pathway inhibitors and PARP inhibition has led to the approval of combinations of these agents. As our understanding of prostate cancer molecular characteristics, use of biomarkers for patient stratification, and drug synergies improves, new approaches are expected to continue to revolutionize how we treat this disease. In this Special Issue, we seek to highlight cutting-edge research advances working to promote and incorporate the use of targeted and rational approaches for advanced and intractable prostate cancer. Studies detailing basic, translational, and clinical work to advance targeted and rational combination strategies are highly encouraged. Work to develop, understand, and incorporate clinical biomarkers to better stratify patients for treatment are also welcomed. Additionally, reviews summarizing different aspects of targeted therapy for prostate cancer and current clinical findings and perspectives will be warmly accepted for review. We express our warmest thanks for considering this opportunity to highlight the latest research in treating advanced prostate cancer.

Dr. Alan P. Lombard
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• prostate cancer
• precision medicine
• targeted therapeutics
• rational drug combinations
• clinical biomarkers